ECYT - The point about bias is well taken. In ECYT's case when an IRC did its own analyses, while the FR++ PFS data remained statistically significant, the overall PFS data did not indicating possible bias. I think confirmation by the IRC for the FR++ population augurs well for the PIII trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.